Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | BCR | P11274 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.45 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 6/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.43 |
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
| ▸ | PDE5A | O76074 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183493 | 0.86 | KCNN3 (0.58) | ABL1BTKKCNN3KCNN2CDK1 | |
| SCHEMBL183297 | 0.84 | KCNN3 (0.58) | KCNN3KCNN2CDK1ADORA3ADORA2A | |
| SCHEMBL246017 | 0.83 | YTHDC1 (0.57) | KCNN3KCNN2CDK1CDK5CDK5R1 | |
| SCHEMBL183290 | 0.81 | CCNE2 (0.59) | KCNN3KCNN2CDK1ADORA3ADORA2A | |
| SCHEMBL183147 | 0.81 | ADORA3 (0.59) | ABL1BTKCDK1CDK5CDK5R1 | |
| SCHEMBL183270 | 0.81 | BCDIN3D (0.46) | KCNN3KCNN2CDK1ADORA3ADORA2A | |
| SCHEMBL19498626 | 0.81 | KCNN3 (0.45) | KCNN3KCNN2CDK1ADORA3ADORA2A | |
| SCHEMBL183502 | 0.80 | CDK2 (0.48) | KCNN3KCNN2CDK1CDK5CDK5R1 | |
| SCHEMBL183054 | 0.79 | KCNN3 (0.45) | KCNN3KCNN2CDK1ADORA3ADORA2A | |
| SCHEMBL183372 | 0.79 | CDK1 (0.46) | KCNN3KCNN2CDK1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| US-20100130516-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-27 | — | — | US | disclosed |
| US-20100130516-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-27 | — | — | US | disclosed |
| US-20100130516-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-27 | — | — | US | disclosed |
| EP-2144911-A2 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch AS (DK) | 2010-01-20 | — | — | EP | disclosed |
| EP-2142547-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008116912-A2 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116912-A2 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116914-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116914-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | ABL1 3096/4885BCR 4235/4885BTK 4163/4885 |
| US-20100130516-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | ABL1 3096/4885BCR 4235/4885BTK 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.